Therapy with TLR7 agonists induces lymphopenia: correlating pharmacology to mechanism in a mouse model. (Q45062234)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22476912%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

title

Therapy with TLR7 agonists induces lymphopenia: correlating pharmacology to mechanism in a mouse model (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22476912%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

0 references

1 reference

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22476912%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Mark Fidock

12

0 references

author name string

Hannah Perkins

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22476912%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Tansi Khodai

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22476912%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Houria Mechiche

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22476912%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Peter Colman

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22476912%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Frances Burden

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22476912%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Carl Laxton

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22476912%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Tom Corey

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22476912%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Deborah Rodrigues

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22476912%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Jaiessh Rawal

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22476912%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Jonathan Heyen

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22476912%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Mike Westby

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22476912%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

Helen Bright

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22476912%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

language of work or name

1 reference

5 April 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22476912%20AND%20SRC:MED&resulttype=core&format=json

Journal of Clinical Immunology

28 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22476912%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

volume

32

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22476912%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

page(s)

1082-1092

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22476912%20AND%20SRC:MED&resulttype=core&format=json

28 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22476912%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1007/s10875-012-9687-y

28 January 2020

exact match

0 references

cites work

The global burden of hepatitis C

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

A target on the move: innate and adaptive immune escape strategies of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

Innate immune evasion by hepatitis C virus and West Nile virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

Hepatitis C virus evasion of adaptive immune responses: a model for viral persistence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

Peginterferon and ribavirin treatment for hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

Treating viral hepatitis C: efficacy, side effects, and complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

Innate immune recognition of viral infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

Discovery of ANA975: an oral prodrug of the TLR-7 agonist isatoribine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

Investigating Toll-Like Receptor Agonists for Potential To Treat Hepatitis C Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

Toll-like receptor-7 agonist administered subcutaneously in a prolonged dosing schedule in heavily pretreated recurrent breast, ovarian, and cervix cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

TLR7 agonist 852A inhibition of tumor cell proliferation is dependent on plasmacytoid dendritic cells and type I IFN.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

Triggering TLR7 in mice induces immune activation and lymphoid system disruption, resembling HIV-mediated pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

Pharmacokinetics and tolerance of intravenous and intramuscular recombinant alpha 2 interferon in patients with malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

Transcriptional networks in plasmacytoid dendritic cells stimulated with synthetic TLR 7 agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

Activation of anti-hepatitis C virus responses via Toll-like receptor 7.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

Impaired expression and function of toll-like receptor 7 in hepatitis C virus infection in human hepatoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10875-012-9687-Y

Effects of interferon on circadian changes in blood pressure and heart rate variability in patients with chronic hepatitis

21 January 2018

1 reference

12 December 2020

CpG oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans

1 reference

12 December 2020

Masked oral prodrugs of toll-like receptor 7 agonists: a new approach for the treatment of infectious disease.

1 reference

12 December 2020

Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans

1 reference

12 December 2020

Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia

1 reference

12 December 2020